Spugnini Enrico Pierluigi, Sonveaux Pierre, Stock Christian, Perez-Sayans Mario, De Milito Angelo, Avnet Sofia, Garcìa Abel Garcìa, Harguindey Salvador, Fais Stefano
Anti-Cancer Drug Section, Department of Drug Research and Medicine Evaluation, Istituto Superiore di Sanità (National Institute of Health), Rome, Italy.
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology, Université Catholique de Louvain (UCL), Brussels, Belgium.
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2715-26. doi: 10.1016/j.bbamem.2014.10.015. Epub 2014 Oct 20.
Although cancer is characterized by an intratumoral genetic heterogeneity, a totally deranged pH control is a common feature of most cancer histotypes. Major determinants of aberrant pH gradient in cancer are proton exchangers and transporters, including V-ATPase, Na+/H+ exchanger (NHE), monocarboxylate transporters (MCTs) and carbonic anhydrases (CAs). Thanks to the activity of these proton transporters and exchangers, cancer becomes isolated and/or protected not only from the body reaction against the growing tumor, but also from the vast majority of drugs that when protonated into the acidic tumor microenvironment do not enter into cancer cells. Proton transporters and exchangers represent a key feature tumor cells use to survive in the very hostile microenvironmental conditions that they create and maintain. Detoxifying mechanisms may thus represent both a key survival option and a selection outcome for cells that behave as unicellular microorganisms rather than belonging to an organ, compartment or body. It is, in fact, typical of malignant tumors that, after a clinically measurable yet transient initial response to a therapy, resistant tumor clones emerge and proliferate, thus bursting a more malignant behavior and rapid tumor progression. This review critically presents the background of a novel and efficient approach that aims to fight cancer through blocking or inhibiting well characterized proton exchangers and transporters active in human cancer cells. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
尽管癌症的特征是肿瘤内存在基因异质性,但pH调控完全紊乱是大多数癌症组织类型的共同特征。癌症中异常pH梯度的主要决定因素是质子交换体和转运体,包括V-ATP酶、钠/氢交换体(NHE)、单羧酸转运体(MCT)和碳酸酐酶(CA)。由于这些质子转运体和交换体的活性,癌症不仅能够隔离和/或抵御机体对生长肿瘤的反应,还能抵御绝大多数药物,因为这些药物在质子化进入酸性肿瘤微环境后无法进入癌细胞。质子转运体和交换体是肿瘤细胞在其创造和维持的极具敌意的微环境条件下赖以生存的关键特征。因此,解毒机制可能既是关键的生存选择,也是那些表现得如同单细胞微生物而非属于某个器官、腔室或机体的细胞的选择结果。事实上,恶性肿瘤的典型特征是,在对治疗产生临床上可测量但短暂的初始反应后,耐药肿瘤克隆会出现并增殖,从而表现出更恶性的行为和肿瘤的快速进展。本综述批判性地介绍了一种新颖且有效的方法的背景,该方法旨在通过阻断或抑制在人类癌细胞中活跃的、已明确特征的质子交换体和转运体来对抗癌症。本文是名为:癌症中的膜通道和转运体的特刊的一部分。